Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
Next >
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
October 03, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
August 26, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
August 24, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
August 23, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 02, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
July 18, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Second Quarter Financial Results
July 12, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
May 26, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 24, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
May 05, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 04, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 03, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
April 28, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
April 22, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report First Quarter Financial Results
April 12, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
March 26, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
March 25, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
March 18, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
February 15, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
February 03, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Provides Update on Parsaclisib and MCLA-145
January 25, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
January 18, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
December 14, 2021
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
December 14, 2021
From
Incyte
Via
Business Wire
Tickers
INCY
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 11, 2021
From
Incyte
Via
Business Wire
Tickers
INCY
MOR
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
December 11, 2021
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
November 09, 2021
From
Incyte
Via
Business Wire
Tickers
INCY
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
November 04, 2021
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 02, 2021
From
Incyte
Via
Business Wire
Tickers
INCY
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
November 01, 2021
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.